We have pioneered a AI-driven technology that can measure metabolite masses fast and inexpensively. Using our proprietary database and machine-learning algorithm, we reduce the need for these additional experiments, predict the identity of each metabolite mass, and integrate these data with other large-scale molecular datasets such as genomics and proteomics.
ReviveMed uniquely overcomes the difficulties of identifying a large set of metabolites for each patient, based on technology developed at The Fraenkel Lab at MIT and published in Nature Methods. It further translates metabolomic data into novel therapeutic insights for drug and drug response biomarker discovery. Currently, ReviveMed is collaborating with tier-one pharmaceutical companies to support their drug discovery programs and in pursuing internal drug discovery, initially focused on metabolic diseases.
No products posted yet
No services posted yet
This data is part of our proprietary analytics report:
This service is currently only supported on the desktop screens, please, use this service from your desktop or laptop for correct visualization and functionality